jnj-79635322
mAbexperimentalTri-specific
Clinical trial activity
4 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Nov 22, 2022 (NCT05652335)
Timeline
No events for the selected filters.
Indications
Mechanism of action
CD3E activator
- G-protein coupled receptor family C group 5 member DBINDING AGENT
binding agent - GPRC5D
- BCMABINDING AGENT
BCMA binding agent
Chemistry & pharmacology
- Multi-specific
- Yes (Tri-specific)
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07266441 | Phase 2 | Mar 17, 2026 | — |
| NCT07258511 | Phase 3 | Feb 20, 2026 | — |
| NCT06768489 | Phase 1 | Dec 4, 2024 | — |
| NCT05652335 | Phase 1 | Nov 22, 2022 | — |
Showing 4 of 4 trials
Page 1 / 1